Navigation Links
Icahn Asks Amylin to Allow Discussions With Eastbourne
Date:4/23/2009

NEW YORK, April 23 /PRNewswire/ -- Carl Icahn announced today that he had sent the following letter to James Wilson, Lead Independent Director of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN).

                                        April 23, 2009

    Mr. James Wilson
    Lead Independent Director
    Amylin Pharmaceuticals, Inc.
    9360 Towne Centre Drive
    San Diego, CA  92121

    Dear Jim:

    If you are really serious about settling what you consider a debilitating
    proxy contest, I believe it is mandatory for you to take the necessary
    action to allow Eastbourne and myself to talk without the threat of your
    poison pill and Section 203 preventing these discussions.  It is almost
    absurd that I and Eastbourne, separately, have had to ask you a number of
    times during last week and the week before to get permission to have these
    talks.  As I have said, even in a dictatorship parties that disagree with
    the ruling regime are allowed to talk to each other.  But not at Amylin.

    I sincerely believe that as a result of these discussions and subsequent
    discussions among the three of us, there will be enough common ground to
    resolve the matter.  What exactly are you afraid of?  The alternative is
    for the Company and its stockholders to continue to be distracted because
    of the inexplicable intransigence of the current Board which continues to
    evidence itself in so many ways, e.g. the poison pill, the poison puts,
    and the failure to heed the views of your co-founder, Howard E. Greene,
    Jr., regarding Joseph Cook's board seat.

    I look forward to your prompt response.

                                        Sincerely,

                                        Carl Icahn

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY CARL C. ICAHN, DR. ALEXANDER J. DENNER, DR. THOMAS F. DEUEL, MR. JULES HAIMOVITZ, DR. PETER LIEBERT, DR. DAVID SIDRANSKY, MR. MAYU SRIS, MR. JEFFREY MECKLER, DR. ERIC ENDE, ICAHN Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Enterprises G.P. Inc., Icahn Enterprises Holdings L.P., IPH GP LLC, Icahn Capital L.P., Icahn Onshore LP, Icahn Offshore LP, Beckton Corp., AND CERTAIN OF THEIR RESPECTIVE AFFILIATES FROM THE STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC, FOR USE AT ITS ANNUAL MEETING WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN ANY SUCH PROXY SOLICITATION. WHEN COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE AVAILABLE TO STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC. FROM THE PARTICIPANTS AT NO CHARGE AND WILL ALSO BE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV.

INFORMATION RELATING TO THE PARTICIPANTS IN THIS PROXY SOLICITATION IS CONTAINED IN SCHEDULE 14A FILED BY THE PARTICIPANTS WITH THE SECURITIES AND EXCHANGE COMMISSION, WHICH DOCUMENTS ARE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV.


'/>"/>
SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Icahn Responds to Cornelius
2. Icahn Confirms Intention to Nominate Three Directors at Biogen
3. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
4. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
5. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
6. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
7. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added ... is a two-hour team-building package designed for groups of 10-30 people. Guests ... which include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with ...
(Date:5/18/2017)... , ... May 17, 2017 ... ... standards with psychonneuroendocrine stress expertise, and further enhances its scientific power by ... Douglas A. Granger, Ph.D., has agreed to join the scientific advisory board. ...
(Date:5/18/2017)... ... May 17, 2017 , ... HOLLOWAY AMERICA, a leading ... and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution Lift™, a new precision-controlled ... improvement in technology comes on the heels of HOLLOWAY’s release of the intelliVessel™, ...
(Date:5/18/2017)... ... 2017 , ... When James Sherley, was notified earlier this year that his company Asymmetrex ... 2017 by The Silicon Review , he was not surprised as others might be. ... but this recognition by Silicon Valley was particularly meaningful. Our selection by ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):